Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status

Jakub Styk1,2,3, Zuzana Pös2,3,4, Ondrej Pös2,3

  • 1Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.

The EPMA Journal
|March 3, 2023
PubMed

Insights

Microsatellite instability (MSI) detection is shifting from low-throughput methods to high-throughput massively parallel sequencing (MPS). This advancement enables predictive, preventive, and personalized medicine (3PM) through efficient patient stratification.

Area of Science:

  • Genomics
  • Cancer Biology
  • Bioinformatics

Background:

  • Microsatellite instability (MSI) is a genomic alteration resulting from DNA mismatch repair (MMR) failure.
  • Traditional MSI detection methods are low-throughput and require both tumor and healthy samples.
  • Recent advancements highlight the potential of massively parallel sequencing (MPS) for MSI assessment.

Purpose of the Study:

  • To comprehensively analyze high-throughput strategies and computational tools for MSI calling and assessment.
  • To discuss the detection of MSI status using current MPS blood-based methods.
  • To explore the potential of MSI detection in advancing Predictive, Preventive, and Personalised Medicine (3PM).

Main Methods:

  • Analysis of whole-genome, whole-exome, and targeted sequencing approaches for MSI detection.
  • Review of computational tools for MSI event assessment.
  • Discussion of current blood-based MPS methods for MSI status determination.

Main Results:

  • High-throughput strategies, particularly MPS, offer significant advantages over traditional methods for MSI detection.
  • Minimally invasive MPS methods show promise for clinical integration.
  • MPS facilitates patient stratification for tailored medical decisions.

Conclusions:

  • MPS technologies are poised to revolutionize MSI detection, enabling a shift towards 3PM.
  • Further development is needed to address technical and cellular/molecular challenges for routine clinical application.
  • Efficient MSI status determination is crucial for personalized cancer care and decision-making.